Oric Pharmaceuticals Inc (ORIC) Stock Price, Quote & News

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 388 5600

Website: www.oricpharma.com

Address:

240 E. Grand Ave, 2nd Floor, South San Francisco, United States

Camelinvesting Mar. 14 at 11:14 PM

$ORIC price target 🎯?

0 · Reply

th3_fail_k1ng Mar. 11 at 11:02 PM

$ORIC January 14th this stock literally had my name on it on that alone I bought in . Aside from ownership, funding, catalysts and a 40% short interest you gotta respect when the universe speaks. This will be another one to watch. Mark it.

0 · Reply

tganzie1 Mar. 10 at 1:35 PM

$ORIC boom as i said yesterday an institution bought almost 300 thousand shares into the close smart money buy dumb money panic and sold

0 · Reply

th3_fail_k1ng Mar. 10 at 4:03 AM

$ORIC thank for sharing news that not only has nothing to do directly with this company or their lead drug candidates but also for completely and intentionally misrepresenting the source (sudo criminal conduct btw). Here's the actual statement, not by ORIC mind you. Didn't see a need to post it personally before now but since I can't take a day off here you go. Small upside, almost maximum short shares borrowed and trapped now cause we're not dumb around here and tutes aren't exactly gonna sell off when they own practically every share for no reason.

0 · Reply

tganzie1 Mar. 9 at 9:17 PM

$ORIC this will bounce tomorrow. Did you see someone or institution just bought almost 300,000 at 11.65

0 · Reply

topstockalerts Mar. 9 at 7:22 PM

Oric Pharmaceuticals said Ipsen will withdraw Tazverik (tazemetostat) from all indications after secondary hematologic malignancies were observed in the Phase 3 SYMPHONY-1 trial in relapsed/refractory follicular lymphoma, where the drug was tested with lenalidomide and rituximab. An independent monitoring committee concluded the risks may outweigh the potential benefits. Wolfe Research analyst Kalpit Patel said the move is a negative signal for the broader EZH2 inhibitor space, though the clinical settings differ. Pfizer’s mevrometostat and Oric’s rinzimetostat are being developed for metastatic castration-resistant prostate cancer, while the issue with Tazverik occurred in follicular lymphoma. He warned investors may worry that safety signals involving secondary malignancies could affect perception of other EZH2-targeting drugs. $ORIC

0 · Reply

medguy Mar. 9 at 6:20 PM

Looking for bounce $OLMA $ORIC $TRVI $BRAI

0 · Reply

notreload_ai Mar. 9 at 3:48 PM

$ORIC shares fell after Ipsen pulled Tazverik from all markets due to safety concerns in a key trial. Tazverik sales were already weak—a blow to confidence in similar EZH2 drugs like ORIC’s, even if they are not the same. https://notreload.xyz/ezh2-class-hit-oric-down-after-tazverik-withdrawal/

0 · Reply

lebranjames Mar. 9 at 3:27 PM

$ORIC anyone know why this down today

1 · Reply

th3_fail_k1ng Mar. 7 at 6:18 PM

$ORIC 3 month chart long double bottom, been here a minute, gonna add more Monday around 13.20 in the opening drop as par for the course before the real show starts. My last post here for awhile wanna keep this one off the retailradar as long a possible.

0 · Reply

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Feb 23, 2026, 4:05 PM EST - 20 days ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

Feb 18, 2026, 5:14 PM EST - 25 days ago

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 5, 2026, 4:01 PM EST - 5 weeks ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Jan 20, 2026, 1:36 PM EST - 7 weeks ago

ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside

Jan 13, 2026, 4:35 PM EST - 2 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:30 AM EST - 2 months ago

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

Jan 6, 2026, 4:05 PM EST - 2 months ago

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 7, 2025, 1:38 AM EST - 3 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript

Dec 5, 2025, 8:00 PM EST - 3 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 5, 2025, 1:00 AM EST - 3 months ago

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 4, 2025, 9:45 PM EST - 3 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Dec 3, 2025, 4:01 PM EST - 3 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Dec 3, 2025, 6:45 AM EST - 3 months ago

Top 3 Health Care Stocks That May Rocket Higher In December

LRMR PRGO

Dec 1, 2025, 8:00 AM EST - 3 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Nov 24, 2025, 4:05 PM EST - 3 months ago

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 4:10 PM EST - 4 months ago

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

Nov 13, 2025, 4:05 PM EST - 4 months ago

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

Nov 6, 2025, 4:00 PM EST - 4 months ago

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Oct 27, 2025, 8:30 AM EDT - 5 months ago

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

Sep 3, 2025, 7:37 PM EDT - 6 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

Aug 18, 2025, 4:05 PM EDT - 7 months ago

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

Aug 12, 2025, 4:05 PM EDT - 7 months ago

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

May 29, 2025, 11:15 AM EDT - 10 months ago

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

May 28, 2025, 4:05 PM EDT - 10 months ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 28, 2025, 4:05 PM EDT - 10 months ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025, 8:00 AM EDT - 10 months ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 5, 2025, 4:05 PM EDT - 11 months ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Apr 28, 2025, 4:30 PM EDT - 11 months ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 22, 2025, 9:15 AM EDT - 11 months ago

ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

Mar 25, 2025, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Feb 25, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Feb 18, 2025, 4:05 PM EST - 1 year ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Jan 13, 2025, 8:05 AM EST - 1 year ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 6, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 1, 2024, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2024, 4:15 PM EDT - 1 year ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 26, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 5, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 17, 2024, 1:00 PM EDT - 1 year ago

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 16, 2024, 4:59 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

May 6, 2024, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Apr 15, 2024, 4:15 PM EDT - 2 years ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 8, 2024, 8:00 AM EDT - 2 years ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2024, 8:19 AM EDT - 2 years ago

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 11, 2024, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Mar 6, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Camelinvesting Mar. 14 at 11:14 PM

$ORIC price target 🎯?

0 · Reply

th3_fail_k1ng Mar. 11 at 11:02 PM

0 · Reply

tganzie1 Mar. 10 at 1:35 PM

$ORIC boom as i said yesterday an institution bought almost 300 thousand shares into the close smart money buy dumb money panic and sold

0 · Reply

th3_fail_k1ng Mar. 10 at 4:03 AM

0 · Reply

tganzie1 Mar. 9 at 9:17 PM

$ORIC this will bounce tomorrow. Did you see someone or institution just bought almost 300,000 at 11.65

0 · Reply

topstockalerts Mar. 9 at 7:22 PM

0 · Reply

medguy Mar. 9 at 6:20 PM

Looking for bounce $OLMA $ORIC $TRVI $BRAI

0 · Reply

notreload_ai Mar. 9 at 3:48 PM

0 · Reply

lebranjames Mar. 9 at 3:27 PM

$ORIC anyone know why this down today

1 · Reply

th3_fail_k1ng Mar. 7 at 6:18 PM

0 · Reply

th3_fail_k1ng Mar. 3 at 3:13 AM

$ORIC hey two new guys, please stop cross threading and pumping the stock. The stock does well because there is no retail on it, it's all institutional investors over owned at 117% with a strategic investment of 7% ownership by Pfizer that is completely separate so 124% ownership and 40% shorted. The more retail show up the worse off the stock is going to be. Because institutions don't let shorts loose. Just enjoy the ride and chill out, some of us have been here for a while incognito and would like it to stay that way thanks

0 · Reply

6GodEnergy Feb. 25 at 7:51 PM

$CAVA $AAOI $ORIC $PULM )5(

0 · Reply

Parobull Feb. 25 at 11:11 AM

HCWC watch HCWC $1+ coming FEELS coiled. Profitable microcap. Cashflow positive. Tons of shorts leaning in while borrow dries up. That’s how violent unwinds start. If buyers step in, that .50s gap could close quickly. Float size makes it dangerous. $HARP $FATE $ABUS $ORIC $CLPT

0 · Reply

McMillion1 Feb. 24 at 10:55 PM

$ORIC still only 832 watchers…they will miss this one

1 · Reply

erevnon Feb. 24 at 7:36 PM

Citigroup maintains ORIC Pharmaceuticals $ORIC at Buy and raises the price target from $16 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

kshonstocks Feb. 24 at 4:59 PM

$ORIC doing well today https://x.com/Quantumup1/status/2026286371137003897

0 · Reply

Quantumup Feb. 24 at 1:24 PM

Oppenheimer reiterated $ORIC Outperform/$15, and said, ORIC reported fourth quarter and full year 2025 results that support what increasingly feels like a two-shots-on-goal story. $PFE $JNJ TAK AZN NVS $AVBP $BDTX Rinzimetostat continues to look competitive in mCRPC with 55% PSA50, 20% PSA90, and 59% ctDNA clearance, and has now moved into dose optimization ahead of a planned 1H26 Phase 3 start. While Pfizer's upcoming MEVPRO-1 readout will be a pivotal moment for the PRC2 class, we believe rinzi can differentiate on safety and PK. In parallel, enozertinib's exon 20 and PACC data has demonstrated systemic activity and compelling CNS control, with the Phase 3 monotherapy dose selected and combo with subcutaneous amivantamab progressing. We will be hosting ORIC management for a fireside chat during our Healthcare Conference on Wednesday, February 25th at 12:00 PM EST. Reiterate Outperform.

0 · Reply

MOTP Feb. 24 at 9:27 AM

$ORIC https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/oric-cancer-pipeline-progress-and-big-pharma-partnerships-re/amp

0 · Reply

6GodEnergy Feb. 24 at 12:51 AM

+@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $ORIC $MCW $ARMP $OMC ^ on watch

0 · Reply

darioras Feb. 20 at 12:19 PM

$ORIC Earning reports expected for today?

0 · Reply

Magic8BallResponse Feb. 19 at 5:28 PM

$ORIC Wonder who buys this out?

0 · Reply

Market Cap	1.19B
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,579,500
Avg Vol	1,680,754
Day's Range	N/A - N/A
Shares Out	100.36M
Stochastic %K	30%
Beta	1.28
Analysts	Strong Sell
Price Target	$21.23